KR100508044B1 - 에프로사르탄 아르기닌 전하-중화-복합체와 그의 제조 및제형화 방법 - Google Patents

에프로사르탄 아르기닌 전하-중화-복합체와 그의 제조 및제형화 방법 Download PDF

Info

Publication number
KR100508044B1
KR100508044B1 KR10-2000-7001173A KR20007001173A KR100508044B1 KR 100508044 B1 KR100508044 B1 KR 100508044B1 KR 20007001173 A KR20007001173 A KR 20007001173A KR 100508044 B1 KR100508044 B1 KR 100508044B1
Authority
KR
South Korea
Prior art keywords
delete delete
arginine
methylene
carboxyphenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2000-7001173A
Other languages
English (en)
Korean (ko)
Other versions
KR20010022582A (ko
Inventor
망가 알. 구디패티
존 엠. 쥬시치신
나게스와라 알. 팔레푸
고파디 엠. 벤카테시
Original Assignee
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스미스클라인 비참 코포레이션 filed Critical 스미스클라인 비참 코포레이션
Publication of KR20010022582A publication Critical patent/KR20010022582A/ko
Application granted granted Critical
Publication of KR100508044B1 publication Critical patent/KR100508044B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
KR10-2000-7001173A 1997-08-06 1998-08-04 에프로사르탄 아르기닌 전하-중화-복합체와 그의 제조 및제형화 방법 Expired - Fee Related KR100508044B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5499097P 1997-08-06 1997-08-06
US60/054,990 1997-08-06
PCT/US1998/016245 WO1999007365A1 (en) 1997-08-06 1998-08-04 Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation

Publications (2)

Publication Number Publication Date
KR20010022582A KR20010022582A (ko) 2001-03-26
KR100508044B1 true KR100508044B1 (ko) 2005-08-17

Family

ID=21994861

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-7001173A Expired - Fee Related KR100508044B1 (ko) 1997-08-06 1998-08-04 에프로사르탄 아르기닌 전하-중화-복합체와 그의 제조 및제형화 방법

Country Status (26)

Country Link
EP (1) EP1027047B1 (https=)
JP (1) JP4463975B2 (https=)
KR (1) KR100508044B1 (https=)
CN (1) CN1276724A (https=)
AR (1) AR015930A1 (https=)
AT (1) ATE341325T1 (https=)
AU (1) AU739295B2 (https=)
BR (1) BR9811926A (https=)
CA (1) CA2299470C (https=)
CO (1) CO4960666A1 (https=)
CY (1) CY1105851T1 (https=)
CZ (1) CZ296274B6 (https=)
DE (1) DE69836095T2 (https=)
DK (1) DK1027047T3 (https=)
ES (1) ES2273433T3 (https=)
HU (1) HUP0201624A3 (https=)
IL (1) IL134378A (https=)
NO (1) NO317771B1 (https=)
NZ (1) NZ502644A (https=)
PL (1) PL198875B1 (https=)
PT (1) PT1027047E (https=)
SA (1) SA98190592B1 (https=)
TR (1) TR200000350T2 (https=)
TW (1) TW570921B (https=)
WO (1) WO1999007365A1 (https=)
ZA (1) ZA987018B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
ATE289204T1 (de) * 1999-04-28 2005-03-15 Takeda Pharmaceutical Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
KR20120058618A (ko) 2003-01-31 2012-06-07 다이이찌 산쿄 가부시키가이샤 동맥 경화 및 고혈압증의 예방 및 치료를 위한 의약
NO323391B1 (no) 2005-09-28 2007-04-23 Hts Hans Torgersen & Sonn As Barnepose
US20100278909A1 (en) * 2007-06-06 2010-11-04 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
JP5476782B2 (ja) * 2009-04-21 2014-04-23 大正製薬株式会社 アルギニン含有錠剤の製造方法
JP5446716B2 (ja) * 2009-10-21 2014-03-19 大正製薬株式会社 アルギニン及びカルニチン含有錠剤の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
KR100222252B1 (ko) * 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물
JP3214856B2 (ja) * 1990-12-14 2001-10-02 スミスクライン・ビーチャム・コーポレイション イミダゾリル−アルケン酸
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
DE4208052A1 (de) * 1992-03-13 1993-09-16 Bayer Ag Imidazolyl substituierte phenylessigsaeureamide
FR2688781B1 (fr) * 1992-03-23 1994-07-01 Sanofi Elf Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
DE4210787A1 (de) * 1992-04-01 1993-10-07 Bayer Ag Cycloalkyl- und Heterocyclyl substituierte Imidazolylpropensäurederivate
JPH0841053A (ja) * 1994-07-28 1996-02-13 Nkk Corp ヘテロアリールアルキル基を有するピリミジン誘導体及 び該誘導体を有効成分として含有するアンジオテンシン ｉｉ拮抗剤
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
JP3092946B2 (ja) * 1995-12-14 2000-09-25 メルク エンド カンパニー インコーポレーテッド ゴナドトロピン放出ホルモン拮抗剤

Also Published As

Publication number Publication date
WO1999007365A1 (en) 1999-02-18
TW570921B (en) 2004-01-11
EP1027047A1 (en) 2000-08-16
NZ502644A (en) 2002-03-01
ZA987018B (en) 1999-02-08
TR200000350T2 (tr) 2000-12-21
SA98190592B1 (ar) 2006-06-20
NO20000577L (no) 2000-02-29
AU8768898A (en) 1999-03-01
PL198875B1 (pl) 2008-07-31
HUP0201624A2 (hu) 2002-12-28
DE69836095D1 (de) 2006-11-16
AU739295B2 (en) 2001-10-11
NO20000577D0 (no) 2000-02-04
PT1027047E (pt) 2007-01-31
DK1027047T3 (da) 2007-01-29
CA2299470A1 (en) 1999-02-18
ATE341325T1 (de) 2006-10-15
PL341562A1 (en) 2001-04-23
IL134378A0 (en) 2001-04-30
CA2299470C (en) 2010-01-26
KR20010022582A (ko) 2001-03-26
CO4960666A1 (es) 2000-09-25
HUP0201624A3 (en) 2003-03-28
EP1027047B1 (en) 2006-10-04
CN1276724A (zh) 2000-12-13
HK1031688A1 (en) 2001-06-22
ES2273433T3 (es) 2007-05-01
IL134378A (en) 2004-02-19
DE69836095T2 (de) 2007-04-12
CZ2000406A3 (cs) 2000-09-13
EP1027047A4 (en) 2002-09-18
CY1105851T1 (el) 2011-02-02
JP4463975B2 (ja) 2010-05-19
NO317771B1 (no) 2004-12-13
AR015930A1 (es) 2001-05-30
BR9811926A (pt) 2000-08-22
CZ296274B6 (cs) 2006-02-15
JP2001513498A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
US6630498B2 (en) Eprosartan arginyl charge-neutralization-complex and a process for its preparation and formulation
KR100634953B1 (ko) 에프로사르탄을 포함하는 생물학적으로 강화된 경구 고형투여 형태의 제제
US6558699B2 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
EP1233768A1 (en) Carvedilol methanesulfonate
JP4880118B2 (ja) 薬物高充填性の即時放出性または放出を修飾した経口用投与処方およびその製法
KR100508044B1 (ko) 에프로사르탄 아르기닌 전하-중화-복합체와 그의 제조 및제형화 방법
HK1031688B (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
MXPA00001385A (en) Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
MXPA00004791A (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20100729

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110805

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110805

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000